Title : Effects of donepezil on emotional\/behavioral symptoms in Alzheimer's disease patients - Weiner_2000_J.Clin.Psychiatry_61_487 |
Author(s) : Weiner MF , Martin-Cook K , Foster BM , Saine K , Fontaine CS , Svetlik DA |
Ref : J Clin Psychiatry , 61 :487 , 2000 |
Abstract :
BACKGROUND: This open-label study examined the effects of the reversible cholinesterase inhibitor donepezil on emotional/behavioral symptoms in Alzheimer's disease (AD) patients. METHOD: Patients were diagnosed as having probable/possible AD by National Institute of Neurological and Communicative Disorders and Stroke/Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) criteria. This study used the CERAD Behavior Rating Scale for Dementia (CBRSD) and its subscales to evaluate a group of 25 AD patients treated with donepezil. Dosage was increased at 4 months for most patients from 5 to 10 mg q.h.s. Analysis of variance was used to compare scores over a period of 12 months. These patients were also compared, using t tests, to a reference group that had received no donepezil or other anticholinesterase. |
PubMedSearch : Weiner_2000_J.Clin.Psychiatry_61_487 |
PubMedID: 10937606 |
Inhibitor | Aricept~Donepezil~E2020 |
Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA (2000)
Effects of donepezil on emotional\/behavioral symptoms in Alzheimer's disease patients
J Clin Psychiatry
61 :487
Weiner MF, Martin-Cook K, Foster BM, Saine K, Fontaine CS, Svetlik DA (2000)
J Clin Psychiatry
61 :487